

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

1-39. (Cancelled)

40. (Currently Amended) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma *in situ*, ichthyoses, hyperkeratosis and disorders of keratinisation;  
consisting ~~essentially~~ of administering a pharmaceutical composition [[,]] to a patient in need thereof, wherein the pharmaceutical composition consists of a single [[an]] inhibitor of the retinoic acid biosynthetic pathway which [[,]] ~~wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

41. (Currently Amended) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, and hyperkeratosis;  
consisting ~~essentially~~ of administering a pharmaceutical composition [[,]] to a patient in need thereof, wherein the pharmaceutical composition consists of a single [[an]] inhibitor of the retinoic acid biosynthetic pathway which [[,]] ~~wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

42. (Currently Amended) A method of treating psoriasis consisting ~~essentially~~ of administering a pharmaceutical composition [[,]] to a patient in need thereof, wherein the pharmaceutical composition consists of a single [[an]] inhibitor of the retinoic acid biosynthetic pathway which [[,]] ~~wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

43. (Previously Presented) The method of claim 40, wherein the disorder of keratinisation is Darrier's disease.

44. (Currently Amended) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma *in situ*,  
ichthyoses, hyperkeratosis and disorders of keratinisation;

~~comprising by~~ topically administering to skin that is to be treated of a patient in need thereof, a pharmaceutical composition consisting of a single [(an)] inhibitor of the retinoic acid biosynthetic pathway[(,)] ~~which wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

45. (Currently Amended) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, and hyperkeratosis;

~~comprising by~~ topically administering to skin that is to be treated of a patient in need thereof, a pharmaceutical composition consisting of a single [(an)] inhibitor of the retinoic acid biosynthetic pathway[(,)] ~~which wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

46. (Currently Amended) A method of treating psoriasis ~~comprising by~~ topically administering to skin that is to be treated of a patient in need thereof, a pharmaceutical composition consisting of a single [(an)] inhibitor of the retinoic acid biosynthetic pathway[(,)] ~~which wherein said inhibitor~~ is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

47. (Previously Presented) The method of claim 44, wherein the disorder of keratinisation is Darrier's disease.

48. (Currently Amended) A method of ~~treating~~ treating a disease selected from psoriasis, acne vulgaris, actinic keratosis, solar keratosis, squamous carcinoma *in situ*, ichthyoses, hyperkeratosis and disorders of keratinization, ~~comprising~~ consisting of administering a pharmaceutical composition carbenoxolone to a patient in need thereof, wherein the pharmaceutical composition consists of carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

49. (Currently Amended) A method of treating a disease selected from psoriasis, acne vulgaris and hyperkeratosis, ~~comprising~~ consisting of administering a pharmaceutical composition carbenoxolone to a patient in need thereof, wherein the pharmaceutical composition consists of carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

50. (Currently Amended) A method of treating psoriasis ~~comprising~~ consisting of administering a pharmaceutical composition carbenoxolone to a patient in need thereof, wherein the pharmaceutical composition consists of carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

51. (Previously Presented) The method of claim 48 wherein the disorder of keratinization is Darrier's disease.